SCHEMBL9862045

SCHEMBL9862045

C#Cc1cccc(C(=O)O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
ALDH1A1 P00352 5/20 0.46
HPGD P15428 4/20 0.46
KDM4E B2RXH2 3/20 0.46
HSD17B10 Q99714 3/20 0.46
ALOX15 P16050 1/20 0.43
CYP3A4 P08684 3/20 0.42
CYP2C9 P11712 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 2/20 0.42
PTGS2 P35354 2/20 0.42
AKR1C3 P42330 2/20 0.42
HIF1A Q16665 2/20 0.42
USP2 O75604 1/20 0.42
MT-CO2 P00403 1/20 0.42
TTR P02766 1/20 0.42
PLA2G1B P04054 1/20 0.42
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL28861660 0.82 LMNA (0.44) TSHRALDH1A1KDM4EHSD17B10ALOX15
SCHEMBL1352722 0.81 NOTUM (0.48) TSHRALDH1A1HPGDKDM4EHSD17B10
SCHEMBL30675636 0.81 NOTUM (0.48) TSHRALDH1A1HPGDKDM4EHSD17B10
SCHEMBL25044297 0.80 LMNA (0.46) TSHRALDH1A1KDM4EHSD17B10ALOX15
SCHEMBL5666504 0.80 ALDH1A1 (0.46) TSHRALDH1A1HPGDKDM4EHSD17B10
SCHEMBL16961186 0.80
SCHEMBL688471 0.79 ALDH1A1 (0.56) TSHRALDH1A1HPGDKDM4EHSD17B10
Benzene SCHEMBL29290216 0.79 ALDH1A1 (0.56) TSHRALDH1A1HPGDKDM4EHSD17B10
Benzene SCHEMBL27265959 0.79 TSHR (0.61) TSHRALDH1A1HPGDKDM4EHSD17B10
SCHEMBL756585 0.79 TSHR (0.61) TSHRALDH1A1HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351570-B2 Disubstituted alkyne derivatives MERCK PATENT GMBH (DE) 2025-07-08 US disclosed
EP-4324833-A1 ALKYNYLPHENYLBENZAMIDE COMPOUND AND USE THEREOF Shenzhen Newdel Biotech Co., Ltd. (CN) 2024-02-21 EP disclosed
US-11834454-B2 Alkynylphenylbenzamide compounds and applications thereof SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) 2023-12-05 US disclosed
US-11834454-B2 Alkynylphenylbenzamide compounds and applications thereof SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) 2023-12-05 US disclosed
US-11834454-B2 Alkynylphenylbenzamide compounds and applications thereof SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) 2023-12-05 US disclosed
CN-116693414-A Compound with 3CL protease inhibition activity and application thereof 深圳市小分子新药创新中心有限公司 2023-09-05 CN disclosed
US-20230046126-A1 ALKYNYLPHENYLBENZAMIDE COMPOUNDS AND APPLICATIONS THEREOF SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) 2023-02-16 US disclosed
US-20230046126-A1 ALKYNYLPHENYLBENZAMIDE COMPOUNDS AND APPLICATIONS THEREOF SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) 2023-02-16 US disclosed
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-02-16 US disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 EP disclosed
WO-2022217821-A1 ALKYNYLPHENYLBENZAMIDE COMPOUND AND USE THEREOF 深圳市新樾生物科技有限公司 2022-10-20 WO disclosed
CN-113831344-B Propargyl phenyl benzamide compound and application thereof 深圳市新樾生物科技有限公司 2022-09-16 CN disclosed
CN-113831344-A Propargyl phenyl benzamide compound and application thereof 暨南大学 2021-12-24 CN disclosed
WO-2021249969-A1 COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES MERCK PATENT GMBH (DE) 2021-12-16 WO disclosed
EP-3898588-A1 DISUBSTITUTED ALKYNE DERIVATIVES Merck Patent GmbH (DE) 2021-10-27 EP disclosed
WO-2020127960-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-25 WO disclosed
WO-1991009066-A1 HIGH CARBON RESINS AND FOAMS HYPERION CATALYSIS INTERNATIONAL, INC. (US) 1991-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046126-A1 ALKYNYLPHENYLBENZAMIDE COMPOUNDS AND APPLICATIONS THEREOF ALK, NTRK1, ERBB2 TSHR 759/4885ALDH1A1 972/4885HPGD 3179/4885
US-12351570-B2 Disubstituted alkyne derivatives BRCA1, MYC, PCNA TSHR 3500/4885ALDH1A1 414/4885HPGD 745/4885
US-11834454-B2 Alkynylphenylbenzamide compounds and applications thereof ALK, NTRK1, ERBB2 TSHR 759/4885ALDH1A1 972/4885HPGD 3179/4885
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES BRCA1, MYC, PCNA TSHR 3500/4885ALDH1A1 414/4885HPGD 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.